DUBLIN and BUDAPEST, Hungary, Aug.
25, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN) and Gedeon
Richter Plc today announced they will present data on the
investigational drug cariprazine in patients with schizophrenia and
acute mania in bipolar I disorder during the 28th
European College of Neuropsychopharmacology (ECNP) annual congress
in Amsterdam, to be held
August 29 – September 1, 2015.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
Data presented include the first detailed results of cariprazine
for the potential treatment of schizophrenia patients with
predominant negative symptoms.
Richter Poster
Mon., August 31, 12:15-1:45 pm CEST
- Cariprazine as Monotherapy for the Treatment of
Schizophrenia Patients with Predominant Negative Symptoms: A
Double-Blind, Active Controlled Trial (abstract #P.3.d.053),
authored by Debelle, M., Nemeth, G., Szalai, E., Szatmari, B.,
Harsanyi, J., Barabassy, A., Laszlovszky, I.
Allergan and Richter Posters
Mon., August 31, 12:15-1:45 pm CEST
- Long-Term Cariprazine Treatment for the Prevention of
Relapse in Patients With Schizophrenia: A Double-Blind,
Placebo-Controlled Trial (abstract #P.3.d.057), authored by
Durgam, S., Earley, W., Li, R., Li, D., Lu, K., Laszlovszky, I.,
Fleischhacker, W.W., Lieberman, J.A.
- Categorical Improvement Across Mania Symptoms: Pooled
Analyses of Cariprazine Phase II/III Trials (abstract
#P.2.d.014), authored by Durgam, S., Laszlovszky, I., Lu, K., Ruth,
A., Debelle, M., Zukin, S.
Tues., September 1, 12:15-1:45 pm CEST
- Cariprazine Reduces Agitation and Hostility Associated With
Schizophrenia (abstract #P.3.d.073), authored by Citrome, L.,
Lu, K., Ferguson, P., Laszlovszky, I., Earley, W., Durgam, S.
About Cariprazine
Cariprazine, an investigational drug, is an atypical
antipsychotic being developed for the treatment of patients with
schizophrenia and for patients with manic or mixed episodes
associated with bipolar I disorder. The safety and efficacy of
cariprazine was studied in a clinical trial program of more than
2,700 patients with these conditions. In addition, cariprazine is
being investigated for the treatment of bipolar depression and
adjunctive major depressive disorder (MDD) in adults. Cariprazine
was discovered and co-developed by Gedeon Richter Plc and is
licensed to Actavis, now Allergan, in the U.S. and Canada.
About Gedeon Richter
Gedeon Richter Plc. (www.richter.hu), headquartered in
Budapest/Hungary, is a major
pharmaceutical company in Central Eastern Europe, with an expanding
direct presence in Western Europe.
Richter's consolidated sales were approximately EUR 1.1 billion (US$ 1.5
billion), while its market capitalization amounted to
EUR 2.1 billion (US$ 2.5 billion) in 2014. The product portfolio
of Richter covers almost all important therapeutic areas, including
gynaecology, central nervous system, and cardiovascular areas.
Having the largest R&D unit in Central Eastern Europe,
Richter's original research activity focuses on CNS disorders. With
its widely acknowledged steroid chemistry expertise, Richter is a
significant player in the female healthcare field worldwide.
Richter is also active in biosimilar product development.
About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing, manufacturing and
commercializing innovative branded pharmaceuticals, high-quality
generic and over-the-counter medicines and biologic products for
patients around the world.
Allergan markets a portfolio of best-in-class products that
provide valuable treatments for the central nervous system, eye
care, medical aesthetics, gastroenterology, women's health,
urology, cardiovascular and anti-infective therapeutic categories,
and operates the world's third-largest global generics business,
providing patients around the globe with increased access to
affordable, high-quality medicines. Allergan is an industry leader
in research and development, with one of the broadest development
pipelines in the pharmaceutical industry and a leading position in
the submission of generic product applications globally.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives.
For more information, visit Allergan's website at
www.allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law,Allergan disclaims any intent or obligation to
update these forward-looking statements. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the risks associated with acquisition
transactions; the difficulty of predicting the timing or outcome of
FDA approvals or actions, if any; the impact of competitive
products and pricing; market acceptance of and continued demand for
Allergan's products; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Quarterly Report on Form
10-Q for the quarter ended March 31,
2015 (such periodic public filings having been filed under
the "Actavis plc" name) and from time to time in Allergan's other
investor communications . Except as expressly required by law,
Allergan disclaims any intent or obligation to update these
forward-looking statements.
ALLERGAN CONTACTS:
Investors:
Lisa DeFrancesco
(862) 261-7152
Media:
Mark Marmur
(862) 261-7558
GEDEON RICHTER CONTACTS:
Investors:
Katalin
Ordog
+36 1 431 5680
Media:
Zsuzsa Beke
+36 1 431 4888
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-and-gedeon-richter-plc-to-present-data-from-cariprazine-trials-at-european-college-of-neuropsychopharmacology-ecnp-annual-meeting-in-amsterdam-300132683.html
SOURCE Allergan plc; Gedeon
Richter